Connecticut Seal

General Assembly

Amendment

 

January Session, 2015

LCO No. 8244

   
 

*SB0002808244SDO*

Offered by:

 

SEN. LEONE, 27th Dist.

REP. BARAM, 15th Dist.

 

To: Subst. Senate Bill No. 28

File No. 329

Cal. No. 232

"AN ACT CONCERNING MANUFACTURER NAMES AND MEDWATCH REPORTING INFORMATION ON GENERIC DRUG CONTAINERS, THE ELECTRONIC PRESCRIPTION DRUG MONITORING PROGRAM AND PHARMACIST CHANGES TO PRESCRIPTION DRUGS DISPENSED TO CERTAIN PATIENTS. "

Strike everything after the enacting clause and substitute the following in lieu thereof:

"Section 1. Section 20-617 of the general statutes is repealed and the following is substituted in lieu thereof (Effective January 1, 2016):

(a) Each pharmacist shall include on the label of each prescription container: (1) The quantity of prescribed drug placed in such container, in addition to any other information required by law, [; ] and (2) a prominently printed expiration date based on the manufacturer's recommended conditions of use and storage that can be read and understood by the ordinary individual. The expiration date required pursuant to subdivision (2) of this [section] subsection shall be no later than the expiration date determined by the manufacturer.

(b) In addition to the information required to be included on the label of each prescription container pursuant to subsection (a) of this section, each pharmacist shall include on the label of each prescription container or on the receipt or other similar packaging in which the prescription is contained for a drug sold only by generic name, as defined in section 20-14a, and not by brand name, as defined in said section: (1) The name of the manufacturer of the generic drug placed in the container, and (2) the Internet web site address and toll-free telephone number for the United States Food and Drug Administration's safety information and adverse event reporting program (MedWatch).

Sec. 2. (NEW) (Effective July 1, 2015) A pharmacist may not substitute a brand name drug product for a different brand name drug product unless specifically authorized, in writing, by the prescribing practitioner. For purposes of this section, "brand name" means the proprietary or trade name selected by a drug manufacturer and placed upon a drug product, its container, label or wrapping at the time of packaging. "

This act shall take effect as follows and shall amend the following sections:

Section 1

January 1, 2016

20-617

Sec. 2

July 1, 2015

New section